Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1995 Aug;50(8):887–893. doi: 10.1136/thx.50.8.887

Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

J W Upham 1, M J Garlepp 1, A W Musk 1, B W Robinson 1
PMCID: PMC474913  PMID: 7570443

Full text

PDF
887

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts A. S., Falkson G., Goedhals L., Vorobiof D. A., Van der Merwe C. A. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol. 1988 Mar;6(3):527–535. doi: 10.1200/JCO.1988.6.3.527. [DOI] [PubMed] [Google Scholar]
  2. Ardizzoni A., Rosso R., Salvati F., Fusco V., Cinquegrana A., De Palma M., Serrano J., Pennucci M. C., Soresi E., Crippa M. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer. 1991 Jun 15;67(12):2984–2987. doi: 10.1002/1097-0142(19910615)67:12<2984::aid-cncr2820671208>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  3. Austin M. B., Fechner R. E., Roggli V. L. Pleural malignant mesothelioma following Wilms' tumor. Am J Clin Pathol. 1986 Aug;86(2):227–230. doi: 10.1093/ajcp/86.2.227. [DOI] [PubMed] [Google Scholar]
  4. Ball D. L., Cruickshank D. G. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol. 1990 Feb;13(1):4–9. doi: 10.1097/00000421-199002000-00002. [DOI] [PubMed] [Google Scholar]
  5. Bielefeldt-Ohmann H., Fitzpatrick D. R., Marzo A. L., Jarnicki A. G., Himbeck R. P., Davis M. R., Manning L. S., Robinson B. W. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother. 1994 Dec;39(6):347–359. doi: 10.1007/BF01534421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bielefeldt-Ohmann H., Fitzpatrick D. R., Marzo A. L., Jarnicki A. G., Musk A. W., Robinson B. W. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res. 1995 Mar;15(3):213–223. doi: 10.1089/jir.1995.15.213. [DOI] [PubMed] [Google Scholar]
  7. Carbone M., Pass H. I., Rizzo P., Marinetti M., Di Muzio M., Mew D. J., Levine A. S., Procopio A. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene. 1994 Jun;9(6):1781–1790. [PubMed] [Google Scholar]
  8. Carry P. Y., Brachet A., Gilly F. N., Sayag A. C., Petit P. Y., Rochette C., Mulsant P., Guibert B., Braillon G., Banssillon V. A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report. Oncology. 1993 Sep-Oct;50(5):348–352. doi: 10.1159/000227208. [DOI] [PubMed] [Google Scholar]
  9. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellström I., Hellström K. E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994 Feb 1;179(2):523–532. doi: 10.1084/jem.179.2.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cheng J. Q., Jhanwar S. C., Klein W. M., Bell D. W., Lee W. C., Altomare D. A., Nobori T., Olopade O. I., Buckler A. J., Testa J. R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994 Nov 1;54(21):5547–5551. [PubMed] [Google Scholar]
  11. Christmas T. I., Manning L. S., Davis M. R., Robinson B. W., Garlepp M. J. HLA antigen expression and malignant mesothelioma. Am J Respir Cell Mol Biol. 1991 Sep;5(3):213–220. doi: 10.1165/ajrcmb/5.3.213. [DOI] [PubMed] [Google Scholar]
  12. Christmas T. I., Manning L. S., Garlepp M. J., Musk A. W., Robinson B. W. Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res. 1993 Feb;13(1):9–12. doi: 10.1089/jir.1993.13.9. [DOI] [PubMed] [Google Scholar]
  13. Culver K. W., Blaese R. M. Gene therapy for cancer. Trends Genet. 1994 May;10(5):174–178. doi: 10.1016/0168-9525(94)90095-7. [DOI] [PubMed] [Google Scholar]
  14. Davis M. R., Manning L. S., Whitaker D., Garlepp M. J., Robinson B. W. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992 Dec 2;52(6):881–886. doi: 10.1002/ijc.2910520609. [DOI] [PubMed] [Google Scholar]
  15. Davis M. R., Manning L. S., Whitaker D., Garlepp M. J., Robinson B. W. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992 Dec 2;52(6):881–886. doi: 10.1002/ijc.2910520609. [DOI] [PubMed] [Google Scholar]
  16. Davis M. R., Manning L. S., Whitaker D., Garlepp M. J., Robinson B. W. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992 Dec 2;52(6):881–886. doi: 10.1002/ijc.2910520609. [DOI] [PubMed] [Google Scholar]
  17. Demetri G. D., Zenzie B. W., Rheinwald J. G., Griffin J. D. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989 Aug 15;74(3):940–946. [PubMed] [Google Scholar]
  18. Dorai T., Kobayashi H., Holland J. F., Ohnuma T. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol. 1994 Sep;46(3):437–444. [PubMed] [Google Scholar]
  19. Fitzpatrick D. R., Bielefeldt-Ohmann H., Himbeck R. P., Jarnicki A. G., Marzo A. L., Robinson B. W. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors. 1994;11(1):29–44. doi: 10.3109/08977199409015049. [DOI] [PubMed] [Google Scholar]
  20. Gerwin B. I., Lechner J. F., Reddel R. R., Roberts A. B., Robbins K. C., Gabrielson E. W., Harris C. C. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 1987 Dec 1;47(23):6180–6184. [PubMed] [Google Scholar]
  21. Griffin T. W., Richardson C., Houston L. L., LePage D., Bogden A., Raso V. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Cancer Res. 1987 Aug 15;47(16):4266–4270. [PubMed] [Google Scholar]
  22. Hand A. M., Husgafvel-Pursiainen K., Tammilehto L., Mattson K., Linnainmaa K. Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines. Cancer Lett. 1991 Jul 4;58(3):205–210. doi: 10.1016/0304-3835(91)90102-n. [DOI] [PubMed] [Google Scholar]
  23. Hui K. M., Sim T., Foo T. T., Oei A. A. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol. 1989 Dec 1;143(11):3835–3843. [PubMed] [Google Scholar]
  24. June C. H., Bluestone J. A., Nadler L. M., Thompson C. B. The B7 and CD28 receptor families. Immunol Today. 1994 Jul;15(7):321–331. doi: 10.1016/0167-5699(94)90080-9. [DOI] [PubMed] [Google Scholar]
  25. Kafiri G., Thomas D. M., Shepherd N. A., Krausz T., Lane D. P., Hall P. A. p53 expression is common in malignant mesothelioma. Histopathology. 1992 Oct;21(4):331–334. doi: 10.1111/j.1365-2559.1992.tb00403.x. [DOI] [PubMed] [Google Scholar]
  26. Langerak A. W., Dirks R. P., Versnel M. A. Splicing of the platelet-derived-growth-factor A-chain mRNA in human malignant mesothelioma cell lines and regulation of its expression. Eur J Biochem. 1992 Sep 15;208(3):589–596. doi: 10.1111/j.1432-1033.1992.tb17223.x. [DOI] [PubMed] [Google Scholar]
  27. Lauber B., Leuthold M., Schmitter D., Cano-Santos J., Waibel R., Stahel R. A. An autocrine mitogenic activity produced by a pleural human mesothelioma cell line. Int J Cancer. 1992 Apr 1;50(6):943–950. doi: 10.1002/ijc.2910500621. [DOI] [PubMed] [Google Scholar]
  28. Law M. R., Hodson M. E., Turner-Warwick M. Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment. Eur J Respir Dis. 1984 Apr;65(3):162–168. [PubMed] [Google Scholar]
  29. Lee T. C., Zhang Y., Aston C., Hintz R., Jagirdar J., Perle M. A., Burt M., Rom W. N. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res. 1993 Jun 15;53(12):2858–2864. [PubMed] [Google Scholar]
  30. Leong C. C., Robinson B. W., Garlepp M. J. Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes. Int J Cancer. 1994 Oct 15;59(2):212–216. doi: 10.1002/ijc.2910590213. [DOI] [PubMed] [Google Scholar]
  31. Lerner H. J., Schoenfeld D. A., Martin A., Falkson G., Borden E. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer. 1983 Dec 1;52(11):1981–1985. doi: 10.1002/1097-0142(19831201)52:11<1981::aid-cncr2820521102>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  32. Licht T., Fiebig H. H., Bross K. J., Herrmann F., Berger D. P., Shoemaker R., Mertelsmann R. Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer. 1991 Oct 21;49(4):630–637. doi: 10.1002/ijc.2910490427. [DOI] [PubMed] [Google Scholar]
  33. Manning L. S., Bowman R. V., Darby S. B., Robinson B. W. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am Rev Respir Dis. 1989 Jun;139(6):1369–1374. doi: 10.1164/ajrccm/139.6.1369. [DOI] [PubMed] [Google Scholar]
  34. Manning L. S., Whitaker D., Murch A. R., Garlepp M. J., Davis M. R., Musk A. W., Robinson B. W. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer. 1991 Jan 21;47(2):285–290. doi: 10.1002/ijc.2910470219. [DOI] [PubMed] [Google Scholar]
  35. Markman M., Cleary S., Pfeifle C., Howell S. B. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer. 1986 Jul 1;58(1):18–21. doi: 10.1002/1097-0142(19860701)58:1<18::aid-cncr2820580105>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  36. Mavaddat N., Robinson B. W., Rose A. H., Manning L. S., Garlepp M. J. An analysis of the relationship between gamma delta T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity. Immunol Cell Biol. 1993 Feb;71(Pt 1):27–37. doi: 10.1038/icb.1993.3. [DOI] [PubMed] [Google Scholar]
  37. Mayall F. G., Goddard H., Gibbs A. R. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):377–381. doi: 10.1002/path.1711680407. [DOI] [PubMed] [Google Scholar]
  38. Metcalf R. A., Welsh J. A., Bennett W. P., Seddon M. B., Lehman T. A., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B. I. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992 May 1;52(9):2610–2615. [PubMed] [Google Scholar]
  39. Metcalf R. A., Welsh J. A., Bennett W. P., Seddon M. B., Lehman T. A., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B. I. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992 May 1;52(9):2610–2615. [PubMed] [Google Scholar]
  40. Park S., Schalling M., Bernard A., Maheswaran S., Shipley G. C., Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993 Aug;4(4):415–420. doi: 10.1038/ng0893-415. [DOI] [PubMed] [Google Scholar]
  41. Pass H. I., Pogrebniak H. Photodynamic therapy for thoracic malignancies. Semin Surg Oncol. 1992 Jul-Aug;8(4):217–225. doi: 10.1002/ssu.2980080407. [DOI] [PubMed] [Google Scholar]
  42. Ramael M., Buysse C., van den Bossche J., Segers K., van Marck E. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J Pathol. 1992 May;167(1):1–4. doi: 10.1002/path.1711670102. [DOI] [PubMed] [Google Scholar]
  43. Ramael M., Segers K., Van Marck E. Differential immunohistochemical staining for retinoblastoma protein with the antibodies C15 and 1F8 in malignant mesothelioma. Pathol Res Pract. 1994 Feb;190(2):138–141. doi: 10.1016/S0344-0338(11)80703-X. [DOI] [PubMed] [Google Scholar]
  44. Ris H. B., Altermatt H. J., Inderbitzi R., Hess R., Nachbur B., Stewart J. C., Wang Q., Lim C. K., Bonnett R., Berenbaum M. C. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer. 1991 Dec;64(6):1116–1120. doi: 10.1038/bjc.1991.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rusch V. W., Piantadosi S., Holmes E. C. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991 Jul;102(1):1–9. [PubMed] [Google Scholar]
  46. Schmitter D., Lauber B., Fagg B., Stahel R. A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992 May 8;51(2):296–301. doi: 10.1002/ijc.2910510220. [DOI] [PubMed] [Google Scholar]
  47. Smythe W. R., Hwang H. C., Amin K. M., Eck S. L., Davidson B. L., Wilson J. M., Kaiser L. R., Albelda S. M. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 1994 Apr 15;54(8):2055–2059. [PubMed] [Google Scholar]
  48. Solheim O. P., Saeter G., Finnanger A. M., Stenwig A. E. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer. 1992 Jun;65(6):956–960. doi: 10.1038/bjc.1992.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X. F., Shimizu J., Fujiwara H., Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol. 1991 Feb 1;146(3):1077–1082. [PubMed] [Google Scholar]
  50. Takita H., Mang T. S., Loewen G. M., Antkowiak J. G., Raghavan D., Grajek J. R., Dougherty T. J. Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. Ann Thorac Surg. 1994 Oct;58(4):995–998. doi: 10.1016/0003-4975(94)90443-x. [DOI] [PubMed] [Google Scholar]
  51. Townsend S. E., Allison J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993 Jan 15;259(5093):368–370. doi: 10.1126/science.7678351. [DOI] [PubMed] [Google Scholar]
  52. Upham J. W., Musk A. W., van Hazel G., Byrne M., Robinson B. W. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med. 1993 Dec;23(6):683–687. doi: 10.1111/j.1445-5994.1993.tb04727.x. [DOI] [PubMed] [Google Scholar]
  53. Van der Meeren A., Seddon M. B., Betsholtz C. A., Lechner J. F., Gerwin B. I. Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived growth factor-A chain overexpression. Am J Respir Cell Mol Biol. 1993 Feb;8(2):214–221. doi: 10.1165/ajrcmb/8.2.214. [DOI] [PubMed] [Google Scholar]
  54. Versnel M. A., Hagemeijer A., Bouts M. J., van der Kwast T. H., Hoogsteden H. C. Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene. 1988 Jun;2(6):601–605. [PubMed] [Google Scholar]
  55. Vogelzang N. J. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol. 1992 Aug;19(4 Suppl 11):64–71. [PubMed] [Google Scholar]
  56. Von Hoff D. D., Metch B., Lucas J. G., Balcerzak S. P., Grunberg S. M., Rivkin S. E. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res. 1990 Oct;10(5):531–534. doi: 10.1089/jir.1990.10.531. [DOI] [PubMed] [Google Scholar]
  57. Walker C., Bermudez E., Stewart W., Bonner J., Molloy C. J., Everitt J. Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in asbestos-induced rat mesothelioma. Cancer Res. 1992 Jan 15;52(2):301–306. [PubMed] [Google Scholar]
  58. Walker C., Rutten F., Yuan X., Pass H., Mew D. M., Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res. 1994 Jun 15;54(12):3101–3106. [PubMed] [Google Scholar]
  59. Zeng L., Buard A., Monnet I., Boutin C., Fleury J., Saint-Etienne L., Brochard P., Bignon J., Jaurand M. C. In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer. 1993 Sep 30;55(3):515–520. doi: 10.1002/ijc.2910550331. [DOI] [PubMed] [Google Scholar]
  60. Zeng L., Buard A., Monnet I., Boutin C., Fleury J., Saint-Etienne L., Brochard P., Bignon J., Jaurand M. C. In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer. 1993 Sep 30;55(3):515–520. doi: 10.1002/ijc.2910550331. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES